Literature DB >> 12770737

Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes.

Masami Fujita1, Takayuki Enomoto, Yuji Murata.   

Abstract

Multiple genetic changes including activation of proto-oncogenes and inactivation of tumor suppressor gene are involved in the development of human ovarian cancer. We describe such genetic alterations with specific reference to histological subtypes. K-ras activation is specific for mucinous tumors including adenomas. Borderline tumors and carcinomas, suggesting that K-ras activation may be associated with the mucinous differentiation rather than malignant transformation. Inactivation of p53 is detected in 30-40% of ovarian carcinoma. Mutations are more frequently observed in serous carcinomas, but not found in adenomas or rarely found in borderline tumors, suggesting that p53 mutations may be directly involved in malignant transformation. TGFbeta-2 mutations are found in 50% of endometrioid carcinoma, but rarely in other type. Loss of DCC mRNA expression is found in 50% of serous carcinomas but less frequently in other type. Loss of DCC expression is rare in borderline tumors and adenomas, suggesting that inactivation of DCC may be directly involved in malignant transformation. Microsatellite instability (MI) is found in 17% of ovarian carcinomas, and is frequently found in endometrioid carcinomas. Although inactivation of p16 by point mutation or deletion is rare, p16 inactivation by loss of expression is relatively common.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12770737     DOI: 10.1016/s0303-7207(03)00069-8

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  12 in total

1.  CYR61 overexpression associated with the development and poor prognosis of ovarian carcinoma.

Authors:  Huimin Shen; Muyan Cai; Shanshan Zhao; Huan Wang; Mengxiong Li; Shuzhong Yao; Nan Jiang
Journal:  Med Oncol       Date:  2014-07-22       Impact factor: 3.064

2.  Genetic variants in MicroRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response.

Authors:  Dong Liang; Larissa Meyer; David W Chang; Jie Lin; Xia Pu; Yuanqing Ye; Jian Gu; Xifeng Wu; Karen Lu
Journal:  Cancer Res       Date:  2010-11-30       Impact factor: 12.701

3.  Mucinous cystic carcinoma of the pancreas: a unique cell line and xenograft model of a preinvasive lesion.

Authors:  Claudio Sorio; Paola Capelli; Daniele Lissandrini; Patrick S Moore; Piera Balzarini; Massimo Falconi; Giuseppe Zamboni; Aldo Scarpa
Journal:  Virchows Arch       Date:  2005-02-02       Impact factor: 4.064

4.  Lost expression of DCC gene in ovarian cancer and its inhibition in ovarian cancer cells.

Authors:  Liu Meimei; Li Peiling; Li Baoxin; Li Changmin; Zhuang Rujin; Hu Chunjie
Journal:  Med Oncol       Date:  2010-01-07       Impact factor: 3.064

5.  Trefoil factor 1 elevates the malignant phenotype of mucinous ovarian cancer cell through Wnt/β-catenin signaling.

Authors:  Shan Zhao; Yumei Ma; Xianghua Huang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

6.  Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer.

Authors:  HanByoul Cho; Jae-Hoon Kim
Journal:  J Histochem Cytochem       Date:  2009-02-02       Impact factor: 2.479

7.  Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease.

Authors:  Hubert Fleury; Laudine Communal; Euridice Carmona; Lise Portelance; Suzanna L Arcand; Kurosh Rahimi; Patricia N Tonin; Diane Provencher; Anne-Marie Mes-Masson
Journal:  Genes Cancer       Date:  2015-09

8.  Loss of E-cadherin disrupts ovarian epithelial inclusion cyst formation and collective cell movement in ovarian cancer cells.

Authors:  Pui-Wah Choi; Junzheng Yang; Shu-Kay Ng; Colleen Feltmate; Michael G Muto; Kathleen Hasselblatt; Kyle Lafferty-Whyte; Lellean JeBailey; Laura MacConaill; William R Welch; Wing-Ping Fong; Ross S Berkowitz; Shu-Wing Ng
Journal:  Oncotarget       Date:  2016-01-26

9.  Serine protease modulation of Dependence Receptors and EMT protein expression.

Authors:  Kara McNair; Caroline M Forrest; Maria C J Vincenten; L Gail Darlington; Trevor W Stone
Journal:  Cancer Biol Ther       Date:  2018-11-07       Impact factor: 4.742

10.  KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.

Authors:  Veronika Auner; Gernot Kriegshäuser; Dan Tong; Reinhard Horvat; Alexander Reinthaller; Alexander Mustea; Robert Zeillinger
Journal:  BMC Cancer       Date:  2009-04-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.